Day One Biopharmaceuticals Q4 2025 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline PAPL Q3 2025 Earnings Narrowed Loss Beats Estimates by 51 MPLX Q1 2026 Earnings EPS Misses Estimates by 156 Amid Stable Distribution Outlook Fate Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Amid Continued Pipeline Development CBIO Q1 2026 Earnings Narrowed Loss Beats Expectations as Cash Management Remains Focus AIFU Q3 2023 Earnings Strong EPS Amid Market Volatility